- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.12. | Neumora upgraded at RBC Capital Markets on obesity, Parkinson's asset | 13 | Seeking Alpha | ||
| 01.12. | Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline | 16 | Benzinga.com | ||
| 01.12. | Neumora Therapeutics stock rating upgraded by RBC Capital on NLRP3 potential | 3 | Investing.com | ||
| 21.11. | Neumora Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| NEUMORA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 17.11. | Stifel raises Neumora Therapeutics stock price target to $3 from $2 | 5 | Investing.com | ||
| 06.11. | Neumora Therapeutics, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 30.10. | TECX, GKOS, GH, ALGN, NMRA Surge After Hours On Clinical Data And Earnings | 464 | AFX News | WASHINGTON (dpa-AFX) - Several healthcare and life sciences names posted notable gains in after-hours trading, driven by clinical updates, earnings releases, and in some cases, unexplained momentum.Tectonic... ► Artikel lesen | |
| 27.10. | Neumora to initiate phase 1 study of oral obesity pill | 4 | Seeking Alpha | ||
| 27.10. | Neumora Therapeutics stock jumps after positive obesity drug data | 2 | Investing.com | ||
| 27.10. | Neumora-Aktie springt nach positiven Adipositas-Daten und Hochstufung | 9 | Investing.com Deutsch | ||
| 27.10. | Guggenheim upgrades Neumora Therapeutics stock to Buy on obesity data | 13 | Investing.com | ||
| 27.10. | Neumora initiates phase 1 study of second M4 PAM compound | 8 | Investing.com | ||
| 27.10. | Neumora Therapeutics, Inc.: Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898 | 315 | GlobeNewswire (Europe) | NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora's M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical... ► Artikel lesen | |
| 27.10. | Neumora Therapeutics, Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 27.10. | Neumora's obesity drug shows up to 26% weight loss in preclinical studies | 12 | Investing.com | ||
| 23.10. | H.C. Wainwright maintains Buy rating on Neumora stock ahead of obesity drug data | 31 | Investing.com | ||
| 01.10. | Neumora Therapeutics, Inc.: Neumora Therapeutics to Host Virtual R&D Day on October 27 | 9 | GlobeNewswire (USA) | ||
| 16.09. | JPM downgrades Neumora, cites risk of more negative trial news | 33 | Investing.com | ||
| 08.08. | Elevidys sales weaken; Neumora gets into obesity | 7 | BioPharma Dive | ||
| 07.08. | Stifel maintains Hold rating on Neumora Therapeutics stock at $2.00 | 14 | Investing.com |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,50 | +3,14 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| CUREVAC | 3,478 | +1,70 % | Wochenend-Update: Curevac-Aktie im Fokus - was Anleger jetzt wissen müssen! | ||
| AMGEN | 279,55 | -0,50 % | Amneal Pharma, MAbxience: FDA Approves Denosumab Biosimilars Referencing Amgen's Prolia And XGEVA | THOUSAND OAKS (dpa-AFX) - Amneal Pharmaceuticals, Inc. (AMRX) announced late Monday that the U.S. Food and Drug Administration has approved the Biologics Licensing Applications or BLAs for Boncresa... ► Artikel lesen | |
| NOVAVAX | 5,766 | -2,24 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| BIOGEN | 146,80 | -2,23 % | Biogen Inc.: The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS | Long-term data published in JAMA Neurology further illustrate the effects of Biogen's QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants regained... ► Artikel lesen | |
| MAINZ BIOMED | 1,270 | +8,55 % | Mainz BioMed NV: DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio | BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,810 | +3,37 % | Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX) | ||
| INTELLIA THERAPEUTICS | 7,816 | -2,66 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| TEMPUS AI | 55,50 | -2,63 % | How Tempus AI Is Advancing Toward Regulatory Pricing Catch-Up | ||
| BIOCRYST PHARMACEUTICALS | 6,362 | +2,05 % | XFRA BO1: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 51,66 | -0,27 % | Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, Sanofi Open Wallets | SOUTH SAN FRANCISCO (dpa-AFX) - In a holiday-shortened week, the biotech sector saw a wave of FDA approvals, strategic acquisitions, and key clinical trial readouts - alongside several setbacks... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,780 | -0,34 % | Sarepta-Aktie: Das sind positive Entwicklungen! | Die Aktie von Sarepta Therapeutics hat in den vergangenen Wochen deutlich an Aufmerksamkeit gewonnen, nachdem regulatorische und strategische Entwicklungen neue Perspektiven für das Unternehmen eröffnet... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,520 | -4,56 % | Cathie Wood's ARK buys Weride, Pacific Biosciences stocks, sells Ibotta | ||
| EXELIXIS | 38,820 | +2,75 % | Adagene Inc.: Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate | SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG) today announced an amendment to the 2021 collaboration and license agreement with Exelixis.... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,791 | +1,80 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
17.12.2025 / 14:38 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen |
Das Unternehmen NEUMORA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,775 Euro und damit -1,93 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUMORA THERAPEUTICS INC finden Sie auf Wallstreet Online.